CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate...
Phase 1
Nashville, Tennessee, United States and 15 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Nashville, Tennessee, United States and 107 other locations
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...
Phase 1
Nashville, Tennessee, United States and 17 other locations
Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for me ...
Phase 1
Nashville, Tennessee, United States and 13 other locations
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...
Phase 1, Phase 2
Nashville, Tennessee, United States and 22 other locations
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...
Phase 1, Phase 2
Nashville, Tennessee, United States and 53 other locations
enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate...
Phase 1, Phase 2
Nashville, Tennessee, United States and 23 other locations
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
Phase 1
Nashville, Tennessee, United States and 9 other locations
of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate...
Phase 2
Nashville, Tennessee, United States and 25 other locations
clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival.The resear...
Phase 2
Nashville, Tennessee, United States and 29 other locations
Clinical trials
Research sites
Resources
Legal